Cite
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.
MLA
Liu, Xuechao, et al. “Preclinical Development of HQP1351, a Multikinase Inhibitor Targeting a Broad Spectrum of Mutant KIT Kinases, for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.” Cell & Bioscience, vol. 9, no. 1, Oct. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s13578-019-0351-6.
APA
Liu, X., Wang, G., Yan, X., Qiu, H., Min, P., Wu, M., Tang, C., Zhang, F., Tang, Q., Zhu, S., Qiu, M., Zhuang, W., Fang, D. D., Zhou, Z., Yang, D., & Zhai, Y. (2019). Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell & Bioscience, 9(1), N.PAG. https://doi.org/10.1186/s13578-019-0351-6
Chicago
Liu, Xuechao, Guangfeng Wang, Xianglei Yan, Haibo Qiu, Ping Min, Miaoyi Wu, Chunyang Tang, et al. 2019. “Preclinical Development of HQP1351, a Multikinase Inhibitor Targeting a Broad Spectrum of Mutant KIT Kinases, for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.” Cell & Bioscience 9 (1): N.PAG. doi:10.1186/s13578-019-0351-6.